![VintaBio bags $64m to ease viral vector bottleneck VintaBio bags $64m to ease viral vector bottleneck](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt172df06be305e97a/658ae0786476d3040a26de1f/Depositphotos_13482353_S.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
The $64 million in funding has supported the opening of VintaBio’s cell and gene therapy (CGT) facility in Philadelphia, US.
VintaBio’s $64 million funding round was led by Decheng Capital, and the investment supported the development of the contract development manufacturing organization’s (CDMO’s) 22,500 square-foot Philadelphia plant, which has been designed specifically to streamline CGT development and production.
“Over half of the funding has gone toward the facility, which includes not just the infrastructure but also the laboratories” David Radspinner, CEO of VintaBio told BioProcess Insider.
DepositPhotos/jamesgroup
To ease the viral vector bottleneck, the firm will initially “focus on well-proven adherent technology and [is] actively looking at improved productivity and yield in both adherent and suspension technology.”
The facility has approximately 20 employees with an aim of doubling this number by the end of this year. According to Radspinner, Philadelphia provides access to “a diverse array of experts” in the region.
Moreover, “its close proximity to international markets positions it as an ideal base for supporting the industry. With its well-developed infrastructure and resources, the Philadelphia Navy Yard serves as an excellent hub for innovative research and development.”
Why VintaBio?
Radspinner has nearly ten years of experience in the life sciences space and has joined VintaBio from ILC Dover, a New Mountain Capital portfolio company. He has previously worked for companies including Cytiva, Thermo Fisher Scientific, Eli Lilly, and Sanofi.